Abstract:Damage to DNA is caused by ionizing radiation, genotoxic chemicals or collapsed replication forks. When DNA is damaged or cells fail to respond, a mutation that is associated with breast or ovarian cancer may occur. Mammalian cells control and stabilize the genome using a cell cycle checkpoint to prevent damage to DNA or to repair damaged DNA. Checkpoint kinase 2 (Chk2) is one of the important kinases, which strongly affects DNA-damage and plays an important role in the response to the breakage of DNA double-strands and related lesions. Therefore, this study concerns Chk2. Its purpose is to find potential inhibitors using the pharmacophore hypotheses (PhModels) and virtual screening techniques. PhModels can identify inhibitors with high biological activities and virtual screening techniques are used to screen the database of the National Cancer Institute (NCI) to retrieve compounds that exhibit all of the pharmacophoric features of potential inhibitors with high interaction energy. Ten PhModels were generated using the HypoGen best algorithm. The established PhModel, Hypo01, was evaluated by performing a cost function analysis of its correlation coefficient (r), root mean square deviation (RMSD), cost difference, and configuration cost, with the values 0.955, 1.28, 192.51, and 16.07, respectively. The result of Fischer’s cross-validation test for the Hypo01 model yielded a 95% confidence level, and the correlation coefficient of the testing set (rtest) had a best value of 0.81. The potential inhibitors were then chosen from the NCI database by Hypo01 model screening and molecular docking using the cdocker docking program. Finally, the selected compounds exhibited the identified pharmacophoric features and had a high interaction energy between the ligand and the receptor. Eighty-three potential inhibitors for Chk2 are retrieved for further study.

Design checkpoint kinase 2 inhibitors by pharmacophore modeling and virtual screening techniques.

Targeting Chk2 Kinase: Molecular Interaction Maps and Therapeutic Rationale

3D-QSAR Study of Chk1 Kinase Inhibitors Based on Docking

Design, Synthesis and Biological Evaluation of Thienopyridinones As Chk1 Inhibitors

Pharmacophore Modeling and Virtual Screening Studies of Checkpoint Kinase 1 Inhibitors.

Molecular Modeling Study Of Checkpoint Kinase 1 Inhibitors By Multiple Docking Strategies And Prime/Mm-Gbsa Calculation

Characterization of the CHK1 allosteric inhibitor binding site.

Targeting the checkpoint kinases: chemosensitization versus chemoprotection

Drug Discovery Targeting Chk1 and Chk2 Kinases.

Functions and Inhibitors of CHK1 in Cancer Therapy

Structure-based and Shape-Complemented Pharmacophore Modeling for the Discovery of Novel Checkpoint Kinase 1 Inhibitors

Computational Studies on the Binding Mechanism Between Triazolone Inhibitors and Chk1 by Molecular Docking and Molecular Dynamics

Structure-Based Quantitative Structure-Activity Relationship Studies of Checkpoint Kinase 1 Inhibitors

Discovery of potential inhibitors targeting the kinase domain of polynucleotide kinase/phosphatase (PNKP): Homology modeling, virtual screening based on multiple conformations, and molecular dynamics simulation

Implications for Chk1 Regulation: the 1.7 Å Crystal Structure of Human Cell Cycle Checkpoint Kinase Chk1

Structural Requirements of Pyrimidine, Thienopyridine and Ureido Thiophene Carboxamide-Based Inhibitors of the Checkpoint Kinase 1: QSAR, Docking, Molecular Dynamics Analysis.

Design, Synthesis, and Biological Evaluation of 2‐Aminothiazole Derivatives as Novel Checkpoint Kinase 1 (CHK1) Inhibitors

Progress in the Study of Cell Cycle Checkpoint Kinase 1 Inhibitors

Dual Induction of Apoptosis and Senescence in Cancer Cells by Chk2 Activation: Checkpoint Activation As a Strategy Against Cancer.

Molecular Docking and 3D-QSAR Studies on Checkpoint Kinase 1 Inhibitors

3D-QSAR Studies on a Series of Inhibitors Docked into a New Homology Model of the DNA-PK Receptor.